Semaglutide Peptide Dosage Chart: Weekly Doses Explained

The semaglutide dosage chart used by US prescribers begins at 0.25 mg once weekly and increases no sooner than every four weeks, stepping through 0.5 mg, 1 mg, and 1.7 mg before reaching a 2.4 mg weekly maintenance dose for weight management. Ozempic, the type 2 diabetes brand, tops out at 2 mg weekly, and Rybelsus is an oral tablet dosed at 3 mg, 7 mg, or 14 mg once daily. Semaglutide sold online as a "research peptide" is a different category of product entirely: it is not FDA-approved for human use, it has no recognized dosing schedule, and no one should self-inject it based on a vendor's chart.

FDA-Approved Semaglutide Dosage Chart

Every FDA-approved semaglutide product follows a step-up schedule, often called titration. The table below shows the labeled doses for the three brand-name products available in the United States.

Product	Weeks 1-4	Weeks 5-8	Weeks 9-12	Weeks 13-16	Maintenance
Wegovy (weight management)	0.25 mg weekly	0.5 mg weekly	1 mg weekly	1.7 mg weekly	2.4 mg weekly from week 17
Ozempic (type 2 diabetes)	0.25 mg weekly	0.5 mg weekly	1 mg weekly	2 mg weekly (max)	2 mg weekly
Rybelsus (oral, type 2 diabetes)	3 mg daily	7 mg daily	14 mg daily (max)	-	14 mg daily

The 0.25 mg starting dose is a tolerance dose. It is not expected to lower blood sugar meaningfully or drive weight loss on its own, and it exists mainly to let the digestive tract adjust before the dose climbs.

How the Titration Schedule Works

Titration is the practice of starting low and moving up slowly. Semaglutide slows stomach emptying and changes appetite signaling, so a rapid jump in dose tends to produce more nausea, vomiting, and diarrhea.

• Dose increases happen no sooner than every four weeks.
• If side effects are rough, a prescriber may hold the current dose longer instead of pushing higher.
• Wegovy's approved maintenance dose is 2.4 mg weekly; 7.2 mg weekly has been studied in clinical trials but is not the standard approved maintenance dose.
• Ozempic is capped at 2 mg weekly for type 2 diabetes, and it is not FDA-approved for weight loss.
• Missed doses are usually made up within a few days or skipped, never doubled, and the specifics come from the prescriber's instructions.

Why "Research Peptide" Semaglutide Has No Official Dosage Chart

Semaglutide sold as a research peptide is not FDA-approved for human use in the United States. These vials carry labels such as "for laboratory research only" and "not for human consumption," which means no regulator has reviewed their identity, strength, sterility, or safety.

That is the core difference between a prescription drug and a chemical sold for peptides for research purposes. Vials listed among glp-1 research peptides for sale are legal to purchase in many states for bench work, but they are not interchangeable with Ozempic, Wegovy, or Rybelsus.

• There is no published human dosing schedule for a research-grade vial.
• Purity and actual peptide content can vary between batches, even from the same seller.
• Reconstituted vials are not produced under the sterility standards required for injectable drugs.
• Compounded semaglutide from a licensed pharmacy is a separate category, and it still requires a prescription.

Reading a Research Vial Label vs. a Prescription Label

A prescription pen or tablet states the exact dose per unit, such as 0.25 mg, 0.5 mg, or 1 mg, so the math is already done for the patient. A research vial usually lists total milligrams per vial and requires reconstituting powder with bacteriostatic water and calculating concentration, which is laboratory math rather than medical dosing.

When a search for semaglutide peptide buy online leads to a gray-market storefront, the page rarely includes anything resembling a clinical dosage chart. Marketing copy that describes a vendor as a peptide sciences alternative does not change the legal or medical status of the product inside the vial.

Independent core peptides reviews and similar third-party roundups typically test identity and purity, not sterility or human safety. A clean certificate of analysis is not the same thing as FDA approval.

Side Effects and Safety Considerations

Approved semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain.

• Serious but uncommon risks include pancreatitis and gallbladder disease.
• Semaglutide is not recommended during pregnancy, and pregnancy should be avoided while using it.
• Dehydration from vomiting can worsen kidney function.
• Patients should tell their clinician about all other medications, especially insulin and sulfonylureas.

Any dose change should be made with a licensed healthcare professional who can review symptoms, labs, and medical history. A dosage chart found online is a reference point, not a prescription.

Bottom Line

The only semaglutide dosage chart backed by clinical trial data and regulatory review is the titration schedule printed on FDA-approved product labels: 0.25 mg weekly up to 2.4 mg weekly for Wegovy, up to 2 mg weekly for Ozempic, and 3 mg to 14 mg daily for Rybelsus. Research-grade semaglutide has no equivalent schedule, no sterility guarantee, and no approval for human use.

People who want semaglutide for weight or blood sugar management should talk to a prescriber rather than self-dosing from a vial. Semaglutide is a prescription medicine in the United States, not an over-the-counter supplement.

COMMON QUESTIONS

Frequently Asked Questions

What is the standard semaglutide dosage chart?

For weight management, Wegovy starts at 0.25 mg once weekly and increases every four weeks to 0.5 mg, 1 mg, 1.7 mg, and a 2.4 mg maintenance dose. Ozempic for type 2 diabetes follows the same early steps but stops at 2 mg weekly. Rybelsus is an oral tablet that moves from 3 mg to 7 mg to 14 mg once daily.

Is research peptide semaglutide the same as Ozempic?

No. Research-grade semaglutide is sold for laboratory use only and is not FDA-approved for human use in the United States. It has not been evaluated for purity, sterility, or dosing in people, so it should never be injected.

How often can the semaglutide dose be increased?

FDA-approved labeling allows an increase no sooner than every four weeks. Faster increases raise the risk of nausea, vomiting, and dehydration, and some patients stay at a lower dose longer when side effects are significant.